Received Dec 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB072A | — |
Patient was administered only the liquid part of Menveo 2-vial presentations without the lyophilized powder; Patient was administered only the liquid part of Menveo 2-vial presentations without the lyophilized powder; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a definite number of patients who received Men ACWY-CRM NVS (Menveo) (batch number AMVB072A, expiry date 30-APR-2026) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Patient was administered only the liquid part of Menveo 2-vial presentations without the lyophilized powder) and inappropriate dose of vaccine administered (Verbatim: Patient was administered only the liquid part of Menveo 2-vial presentations without the lyophilized powder). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 05-DEC-2025 The reporter reported that 2 patient were administered only the liquid part of Menveo 2-vial presentations without the lyophilized powder.